Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,476,701 papers from all fields of science
Search
Sign In
Create Free Account
daratumumab
Known as:
Anti-CD38 Monoclonal Antibody
A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
5 ML daratumumab 20 MG/ML Injection [Darzalex]
Monoclonal Antibodies
NCIt Antineoplastic Agent Terminology
antigen binding
Broader (1)
Antineoplastic Agents
Narrower (1)
Darzalex
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement
Shweta Deshpande
,
M. Gertz
,
A. Dispenzieri
,
Shaji Kumar
,
S. Parikh
,
Eli Muchtar
Leukemia and Lymphoma
2020
Corpus ID: 212667986
Systemic amyloidosis is a disease caused by protein misfolding, aggregation, and deposition in the form of insoluble material…
Expand
2019
2019
Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
P. Kapoor
,
M. Gertz
,
+19 authors
Shaji K. Kumar
Blood
2019
Corpus ID: 209260885
Background: The current commonly used regimens in newly diagnosed multiple myeloma (NDMM) utilize steroids (dexamethasone or…
Expand
2019
2019
PS1425 RESULTS OF THE DARATUMUMAB MONOTHERAPY EARLY ACCESS TREATMENT PROTOCOL (EAP) IN PATIENTS FROM EUROPE AND RUSSIA WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
G. Cook
,
A. Corso
,
+11 authors
V. Mateos
HemaSphere
2019
Corpus ID: 196572985
| 2019;3:S1 656 Methods: We examined a combined database of clinical and survival information for 314 patients from Brighton and…
Expand
2019
2019
Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen
Thura Win Htut
,
D. Quick
,
+11 authors
K. Thein
Blood
2019
Corpus ID: 209240512
Introduction: Proteasome inhibitors-based regimens are the mainstay of initial therapy for most patients with multiple myeloma…
Expand
2018
2018
Daratumumab-based therapies in patients with AL amyloidosis.
J. Abeykoon
,
S. Zanwar
,
+12 authors
P. Kapoor
2018
Corpus ID: 80716423
8053Background: Treatment options for patients (pts) with relapsed/refractory (RR) AL amyloidosis are limited. Daratumumab (dara…
Expand
Review
2017
Review
2017
Daratumumab Is Safe and Highly Effective in AL Amyloidosis
Jack Khouri
,
Thapa Bicky
,
+6 authors
J. Valent
2017
Corpus ID: 217175974
Introduction: AL amyloidosis remains a challenge to treat due to relapse even with the use of novel agents as well as high dose…
Expand
2017
2017
Adaptability of Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T Cells in Combination with Daratumumab over CAR-Based Approaches
Taylor L Hickman
,
Adrianna Graziano
,
+8 authors
Tooba A. Cheema
2017
Corpus ID: 80444585
Chimeric antigen receptor (CAR)-T cells have demonstrated profound clinical responses against CD19+ B cell malignancies, with…
Expand
2016
2016
Multiple Myeloma Gets Three New Drugs.
Alissa Poh
Cancer Discovery
2016
Corpus ID: 36764436
In the last few weeks, the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome inhibitor…
Expand
Review
2013
Review
2013
Daratumumab. Anti-CD38 monoclonal antibody, treatment of multiple myeloma
P. Richardson
,
H. Lokhorst
,
+7 authors
T. Plesner
Drugs of the future
2013
Corpus ID: 78148879
CD38 is a type II transmembrane glycoprotein that is highly expressed in hematological malignancies, including multiple myeloma…
Expand
2012
2012
Interest resparks in RNAi
G. Sinha
Nature Biotechnology
2012
Corpus ID: 39307614
volume 30 number 11 november 2012 nature biotechnology cells is not well understood, but studies suggest it helps tumor cells…
Expand